Radioactive antibody and immunotherapy combo targets recurrent brain cancer

NCT ID NCT07422363

Not yet recruiting Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new combination for recurrent glioblastoma, a fast-growing brain tumor. The treatment pairs Actimab-A, a radioactive antibody that seeks out cancer cells, with cemiplimab, an immunotherapy that helps the immune system attack tumors. About 30 adults whose cancer has returned after standard treatment will receive the drugs intravenously. The main goals are to find the safest dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Actimab-A (radioactive antibody) plus cemiplimab (immunotherapy)
What this could lead to: If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong: This is a very early phase I trial with only 30 people, focused on safety and dosing. It may not show benefit, and side effects from radiation and immunotherapy could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma gliosarcoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA, IDH-WILDTYPE RECURRENT GLIOSARCOMA RECURRENT WHO GRADE 4 GLIOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.